Bloom, D. E. et al. The Global Economic Burden of Non-communicable Diseases. Geneva: World Economic Forum (2011).
Roth, G. A. et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J. Am. Coll. Cardiol. 70, 1–25 (2017).
N. Engl. J. Med. 348, 2007–2018 (2003).
Bergmann, O. et al. Evidence for cardiomyocyte renewal in humans. Science 324, 98–102 (2009).
Menasché, P. et al. The myoblast autologous grafting in ischemic cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 117, 1189–1200 (2008).
Assmus, B. et al. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. Circ. Heart Fail. 3, 89–96 (2010).
Eur. J. Heart Fail. 12, 721–729 (2010).
Menasché, P. et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur. Heart J. 36, 2011–2017 (2015).
Kastrup, J. et al. Direct intramyocardial plasmid vascular endothelial growth factor-A 165 gene therapy in patients with stable severe angina pectoris: a randomized double-blind placebo-controlled study: the Euroinject One trial. J. Am. Coll. Cardiol. 45, 982–988 (2005).
Zohlnhofer, D. et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients. JAMA 295, 1003–1010 (2006).
Gao, R. et al. A phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J. Am. Coll. Cardiol. 55, 1907–1914 (2010).
Chien, K. R. et al. Regenerating the field of cardiovascular cell therapy. Nat. Biotechnol. 37, 232–237 (2019).
Nat. Protoc. 11, 1775–1781 (2016).
Madonna, R. et al. ESC Working Group on Cellular Biology of the Heart Position paper for Cardiovascular Research: tissue engineering and cell-based therapies for cardiac repair in ischemic heart disease and heart failure. Cardiovasc. Res. 115, 488–500 (2019).
Zhao, Y. et al. Towards chamber specific heart-on-a-chip for drug testing applications. Adv. Drug Deliv. Rev. 165, 60–76 (2020).
Circ. Res. 118, 368–370 (2016).
Litviňuková, M. et al. Cells of the adult human heart. Nature 588, 466–472 (2020).
Hescheler, J. et al. Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart. Circ. Res. 69, 1476–1486 (1991).
Claycomb, W. C. et al. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc. Natl Acad. Sci. USA 95, 2979–2984 (1998).
Eschenhagen, T. et al. Three-dimensional reconstitution of embryonic cardiomyocytes in a collagen matrix: a new heart muscle model system. FASEB J. 11, 683–694 (1997).
Carrier, R. L. et al. Cardiac tissue engineering: cell seeding, cultivation parameters, and tissue construct characterization. Biotechnol. Bioeng. 64, 580–589 (1999).
Watson, S. A. et al. Preparation of viable adult ventricular myocardial slices from large and small mammals. Nat. Protoc. 12, 2623–2639 (2017).
Banyasz, T. et al. Transformation of adult rat cardiac myocytes in primary culture. Exp. Physiol. 93, 370–382 (2008).
Watson, S. A. et al. Biomimetic electromechanical stimulation to maintain adult myocardial slices in vitro. Nat. Commun. 10, 1–15 (2019).
Fischer, C. et al. Long-term functional and structural preservation of precision-cut human myocardium under continuous electromechanical stimulation in vitro. Nat. Commun. 10, 1–12 (2019).
Davidson, M. M. et al. Novel cell lines derived from adult human ventricular cardiomyocytes. J. Mol. Cell. Cardiol. 39, 133–147 (2005).
Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145–1147 (1998).
Cell 126, 663–676 (2006).
Takahashi, K. et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861–872 (2007).
Nat. Rev. Cardiol. 13, 333–349 (2016).
EMBO J. 33, 409–417 (2014).
Burridge, P. W. et al. Chemically defned generation of human cardiomyocytes. Nat. Methods 11, 855–860 (2014).
Ueno, S. et al. Biphasic role for Wnt/β-catenin signaling in cardiac specification in zebrafish and embryonic stem cells. Proc. Natl Acad. Sci. USA 104, 9685–9690 (2007).
Lian, X. et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc. Natl Acad. Sci. USA 109, E1848–E1857 (2012).
ACS Chem. Biol. 6, 192–197 (2011).
Lian, X. et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions. Nat. Protoc. 8, 162–175 (2013).
Squire, J. M. Architecture and function in the muscle sarcomere. Curr. Opin. Struct. Biol. 7, 247–257 (1997).
Gerdes, A. M. et al. Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy. Circulation 86, 426–430 (1992).
Mollova, M. et al. Cardiomyocyte proliferation contributes to heart growth in young humans. Proc. Natl Acad. Sci. USA 110, 1446–1451 (2013).
Olivetti, G. et al. Aging, cardiac hypertrophy and ischemic cardiomyopathy do not affect the proportion of mononucleated and multinucleated myocytes in the human heart. J. Mol. Cell. Cardiol. 28, 1463–1477 (1996).
Wei, S. et al. T-tubule remodeling during transition from hypertrophy to heart failure. Circ. Res. 107, 520–531 (2010).
Circulation 101, 2586–2594 (2000).
Circ. Res. 113, 1219–1230 (2013).
Porter, G. A. et al. Bioenergetics, mitochondria, and cardiac myocyte differentiation. Prog. Pediatr. Cardiol. 31, 75–81 (2011).
Circ. Res. 74, 1065–1070 (1994).
Peters, N. S. et al. Spatiotemporal relation between gap junctions and fascia adherens junctions during postnatal development of human ventricular myocardium. Circulation 90, 713–725 (1994).
Stem Cells Dev. 22, 1991–2002 (2013).
Snir, M. et al. Assessment of the ultrastructural and proliferative properties of human embryonic stem cell-derived cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 285, 2355–2363 (2003).
Vreeker, A. et al. Assembly of the cardiac intercalated disk during pre- and postnatal development of the human heart. PLoS ONE 9, e94722 (2014).
Stem Cells 25, 3038–3044 (2007).
Lieu, D. K. et al. Absence of transverse tubules contributes to non-uniform Ca2+ wavefronts in mouse and human embryonic stem cell-derived cardiomyocytes. Stem Cells Dev. 18, 1493–1500 (2009).
Stem Cells Int. 2017, 5153625 (2017).
Schaaf, S. et al. Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS ONE 6, e26397 (2011).
Sasaki, D. et al. Contractile force measurement of human induced pluripotent stem cell-derived cardiac cell sheet-tissue. PLoS ONE 13, e0198026 (2018).
J. Cardiovasc. Pharmacol. 56, 130–140 (2010).
Chung, S. et al. Mitochondrial oxidative metabolism is required for the cardiac differentiation of stem cells. Nat. Clin. Pract. Cardiovasc. Med. 4, 60–67 (2007).
Circ. Res. 113, 603–616 (2013).
Van Der Velden, J. et al. Isometric tension development and its calcium sensitivity in skinned myocyte-sized preparations from different regions of the human heart. Cardiovasc. Res. 42, 706–719 (1999).
Hasenfuss, G. et al. Energetics of isometric force development in control and volume-overload human myocardium. Comparison with animal species. Circ. Res. 68, 836–846 (1991).
Circulation 85, 1743–1750 (1992).
Pieske, B. et al. Diminished post-rest potentiation of contractile force in human dilated cardiomyopathy: functional evidence for alterations in intracellular Ca2+ handling. J. Clin. Invest. 98, 764–776 (1996).
Mannhardt, I. et al. Human engineered heart tissue: analysis of contractile force. Stem Cell Rep. 7, 29–42 (2016).
Huebsch, N. et al. Miniaturized iPS-cell-derived cardiac muscles for physiologically relevant drug response analyses. Sci. Rep. 6, 1–12 (2016).
Card. Electrophysiol. Clin. 3, 23–45 (2011).
Dangman, K. H. et al. Electrophysiologic characteristics of human ventricular and Purkinje fibers. Circulation 65, 362–368 (1982).
Satin, J. et al. Mechanism of spontaneous excitability in human embryonic stem cell derived cardiomyocytes. J. Physiol. 559, 479–496 (2004).
Mummery, C. et al. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation 107, 2733–2740 (2003).
Ribeiro, M. C. et al. Functional maturation of human pluripotent stem cell derived cardiomyocytes invitro – correlation between contraction force andelectrophysiology. Biomaterials 51, 138–150 (2015).
Scheel, O. et al. Action potential characterization of human induced pluripotent stem cell-derived cardiomyocytes using automated patch-clamp technology. Assay Drug Dev. Technol. 12, 457–469 (2014).
Biol. Open 7, bio035030 (2018).
Bers, D. M. Cardiac excitation-contraction coupling. Nature 415, 198–205 (2002).
PLoS ONE 8, e55266 (2013).
Riedel, M. et al. Functional and pharmacological analysis of cardiomyocytes differentiated from human peripheral blood mononuclear-derived pluripotent stem cells. Stem Cell Rep. 3, 131–141 (2014).
Thompson, S. A. et al. Engraftment of human embryonic stem cell derived cardiomyocytes improves conduction in an arrhythmogenic in vitro model. J. Mol. Cell. Cardiol. 53, 15–23 (2012).
Circ. Res. 10, 306–312 (1962).
Circulation 47, 776–785 (1973).
Physiol. Genomics 44, 245–258 (2012).
Front. Cell Dev. Biol. 5, 50 (2017).
J. Physiol. 598, 2941–2956 (2020).
Kamakura, T. et al. Ultrastructural maturation of human-induced pluripotent stem cell-derived cardiomyocytes in a long-term culture. Circ. J. 77, 1307–1314 (2013).
Ebert, A. et al. Proteasome-dependent regulation of distinct metabolic states during long-term culture of human ipsc-derived cardiomyocytes. Circ. Res. 125, 90–103 (2019).
Shiba, Y. et al. Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. Nature 538, 388–391 (2016).
Stem Cell Rep. 8, 278–289 (2017).
Radisic, M. et al. Functional assembly of engineered myocardium by electrical stimulation of cardiac myocytes cultured on scaffolds. Proc. Natl Acad. Sci. USA 101, 18129–18134 (2004).
Tandon, N. et al. Electrical stimulation systems for cardiac tissue engineering. Nat. Protoc. 4, 155–173 (2009).
J. Mol. Cell. Cardiol. 41, 633–641 (2006).
Godier-Furnémont, A. F. G. et al. Physiologic force-frequency response in engineered heart muscle by electromechanical stimulation. Biomaterials 60, 82–91 (2015).
Kroll, K. et al. Electro-mechanical conditioning of human iPSC-derived cardiomyocytes for translational research. Prog. Biophys. Mol. Biol. 130, 212–222 (2017).
Nunes, S. S. et al. Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nat. Methods 10, 781–787 (2013).
Zimmermann, W. H. et al. Tissue engineering of a differentiated cardiac muscle construct. Circ. Res. 90, 223–230 (2002).
Hansen, A. et al. Development of a drug screening platform based on engineered heart tissue. Circ. Res. 107, 35–44 (2010).
Biomaterials 111, 66–79 (2016).
Breckwoldt, K. et al. Differentiation of cardiomyocytes and generation of human engineered heart tissue. Nat. Protoc. 12, 1177–1197 (2017).
Ulmer, B. M. et al. Contractile work contributes to maturation of energy metabolism in hiPSC-derived cardiomyocytes. Stem Cell Rep. 10, 834–847 (2018).
Uzun, A. U. et al. Ca2+-currents in human induced pluripotent stem cell-derived cardiomyocytes effects of two different culture conditions. Front. Pharmacol. 7, 300 (2016).
Leonard, A. et al. Afterload promotes maturation of human induced pluripotent stem cell derived cardiomyocytes in engineered heart tissues. J. Mol. Cell. Cardiol. 118, 147–158 (2018).
Abilez, O. J. et al. Passive stretch induces structural and functional maturation of engineered heart muscle as predicted by computational modeling. Stem Cells 36, 265–277 (2018).
Anal. Chem. 88, 9862–9868 (2016).
Hirt, M. N. et al. Functional improvement and maturation of rat and human engineered heart tissue by chronic electrical stimulation. J. Mol. Cell. Cardiol. 74, 151–161 (2014).
Ruan, J. L. et al. Mechanical stress conditioning and electrical stimulation promote contractility and force maturation of induced pluripotent stem cell-derived human cardiac tissue. Circulation 134, 1557–1567 (2016).
Ronaldson-Bouchard, K. et al. Advanced maturation of human cardiac tissue grown from pluripotent stem cells. Nature 556, 239–243 (2018).
Ribeiro, A. J. S. et al. Contractility of single cardiomyocytes differentiated from pluripotent stem cells depends on physiological shape and substrate stiffness. Proc. Natl Acad. Sci. USA 112, 12705–12710 (2015).
Rodriguez, M. L. et al. Substrate stiffness, cell anisotropy, and cell-cell contact contribute to enhanced structural and calcium handling properties of human embryonic stem cell-derived cardiomyocytes. ACS Biomater. Sci. Eng. 5, 3876–3888 (2019).
Acta Biomater. 7, 3285–3293 (2011).
Feaster, T. K. et al. Matrigel mattress: a method for the generation of single contracting human-induced pluripotent stem cell-derived cardiomyocytes. Circ. Res. 117, 995–1000 (2015).
Papadaki, M. et al. Tissue engineering of functional cardiac muscle: molecular, structural, and electrophysiological studies. Am. J. Physiol. Heart Circ. Physiol. 280, 168–178 (2001).
Chen, Y. et al. Engineering a freestanding biomimetic cardiac patch using biodegradable poly(lactic-co-glycolic acid) (PLGA) and human embryonic stem cell-derived ventricular cardiomyocytes (hESC-VCMs). Macromol. Biosci. 15, 426–436 (2015).
Jongpaiboonkit, L. et al. An adaptable hydrogel array format for 3-dimensional cell culture and analysis. Biomaterials 29, 3346–3356 (2008).
Chun, Y. W. et al. Combinatorial polymer matrices enhance in vitro maturation of human induced pluripotent stem cell-derived cardiomyocytes. Biomaterials 67, 52–64 (2015).
Feinberg, A. W. et al. Muscular thin films for building actuators and powering devices. Science 317, 1366–1370 (2007).
Herron, T. J. et al. Extracellular matrix-mediated maturation of human pluripotent stem cell-derived cardiac monolayer structure and electrophysiological function. Circ. Arrhythmia Electrophysiol. 9, e003638 (2016).
Fong, A. H. et al. Three-dimensional adult cardiac extracellular matrix promotes maturation of human induced pluripotent stem cell-derived cardiomyocytes. Tissue Eng. Part A 22, 1016–1025 (2016).
Garreta, E. et al. Myocardial commitment from human pluripotent stem cells: rapid production of human heart grafts. Biomaterials 98, 64–78 (2016).
Guyette, J. P. et al. Bioengineering human myocardium on native extracellular matrix. Circ. Res. 118, 56–72 (2016).
Circ. Res. 110, 1023–1034 (2012).
Abecasis, B. et al. Unveiling the molecular crosstalk in a human induced pluripotent stem cell-derived cardiac model. Biotechnol. Bioeng. 116, 1245–1252 (2019).
Dunn, K. K. et al. Coculture of endothelial cells with human pluripotent stem cell-derived cardiac progenitors reveals a differentiation stage-specific enhancement of cardiomyocyte maturation. Biotechnol. J. 14, 1800725 (2019).
Burridge, P. W. et al. Multi-cellular interactions sustain long-term contractility of human pluripotent stem cell-derived cardiomyocytes. Am. J. Transl. Res. 6, 724–735 (2014).
Shimizu, T. et al. Fabrication of pulsatile cardiac tissue grafts using a novel 3-dimensional cell sheet manipulation technique and temperature-responsive cell culture surfaces. Circ. Res. 90, e40–e48 (2002).
Correia, C. et al. 3D aggregate culture improves metabolic maturation of human pluripotent stem cell derived cardiomyocytes. Biotechnol. Bioeng. 115, 630–644 (2018).
Eng, G. et al. Autonomous beating rate adaptation in human stem cell-derived cardiomyocytes. Nat. Commun. 7, 1–10 (2016).
Ma, Z. et al. Self-organizing human cardiac microchambers mediated by geometric confinement. Nat. Commun. 6, 1–10 (2015).
Goldfracht, I. et al. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications. Acta Biomater. 92, 145–159 (2019).
Boudou, T. et al. A microfabricated platform to measure and manipulate the mechanics of engineered cardiac microtissues. Tissue Eng. Part A 18, 910–919 (2012).
Biomaterials 35, 3819–3828 (2014).
Shadrin, I. Y. et al. Cardiopatch platform enables maturation and scale-up of human pluripotent stem cell-derived engineered heart tissues. Nat. Commun. 8, 1–15 (2017).
Macqueen, L. A. et al. A tissue-engineered scale model of the heart ventricle. Nat. Biomed. Eng. 2, 930–941 (2018).
Thavandiran, N. et al. Design and formulation of functional pluripotent stem cell-derived cardiac microtissues. Proc. Natl Acad. Sci. USA 110, E4698–E4707 (2013).
Abecasis, B. et al. Toward a microencapsulated 3D hiPSC-derived in vitro cardiac microtissue for recapitulation of human heart microenvironment features. Front. Bioeng. Biotechnol. 8, 1163 (2020).
Giacomelli, E. et al. Human-iPSC-derived cardiac stromal cells enhance maturation in 3D cardiac microtissues and reveal non-cardiomyocyte contributions to heart disease. Cell Stem Cell 26, 862–879 (2020).
Ronaldson-Bouchard, K. et al. Engineering of human cardiac muscle electromechanically matured to an adult-like phenotype. Nat. Protoc. 14, 2781–2817 (2019).
Yang, X. et al. Fatty acids enhance the maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cell Rep. 13, 657–668 (2019).
Hu, D. et al. Metabolic maturation of human pluripotent stem cellderived cardiomyocytes by inhibition of HIF1α and LDHA. Circ. Res. 123, 1066–1079 (2018).
Correia, C. et al. Distinct carbon sources affect structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. Sci. Rep. 7, 1–17 (2017).
Li, M. et al. Thyroid hormone action in postnatal heart development. Stem Cell Res. 13, 582–591 (2014).
Yang, X. et al. Tri-iodo-l-thyronine promotes the maturation of human cardiomyocytes-derived from induced pluripotent stem cells. J. Mol. Cell. Cardiol. 72, 296–304 (2014).
Parikh, S. S. et al. Thyroid and glucocorticoid hormones promote functional T-tubule development in human-induced pluripotent stem cell-derived cardiomyocytes. Circ. Res. 121, 1323–1330 (2017).
Yoshida, S. et al. Maturation of human induced pluripotent stem cell-derived cardiomyocytes by soluble factors from human mesenchymal stem cells. Mol. Ther. 26, 2681–2695 (2018).
Circ. Res. 87, 781–788 (2000).
Sucharov, C. C. et al. A β1-adrenergic receptor CaM kinase II-dependent pathway mediates cardiac myocyte fetal gene induction. Am. J. Physiol. Heart Circ. Physiol. 291, 1299–1308 (2006).
Patrizio, M. et al. cAMP-mediated β-adrenergic signaling negatively regulates Gq-coupled receptor-mediated fetal gene response in cardiomyocytes. J. Mol. Cell. Cardiol. 45, 761–769 (2008).
Földes, G. et al. Modulation of human embryonic stem cell-derived cardiomyocyte growth: a testbed for studying human cardiac hypertrophy? J. Mol. Cell. Cardiol. 50, 367–376 (2011).
Lieu, D. K. et al. Mechanism-based facilitated maturation of human pluripotent stem cell-derived cardiomyocytes. Circ. Arrhythmia Electrophysiol. 6, 191–201 (2013).
Liu, J. et al. Facilitated maturation of Ca2+ handling properties of human embryonic stem cell-derived cardiomyocytes by calsequestrin expression. Am. J. Physiol. Cell Physiol. 297, 152–159 (2009).
Chow, M. Z. et al. Epigenetic regulation of the electrophysiological phenotype of human embryonic stem cell-derived ventricular cardiomyocytes: insights for driven maturation and hypertrophic growth. Stem Cells Dev. 22, 2678–2690 (2013).
PLoS ONE 7, e45010 (2012).
Biermann, M. et al. Epigenetic priming of human pluripotent stem cell‐derived cardiac progenitor cells accelerates cardiomyocyte maturation. Stem Cells 37, 910–923 (2019).
Babiarz, J. E. et al. Determination of the human cardiomyocyte mRNA and miRNA differentiation network by fine-scale profiling. Stem Cells Dev. 21, 1956–1965 (2012).
Kumar, N. et al. Assessment of temporal functional changes and miRNA profiling of human iPSC-derived cardiomyocytes. Sci. Rep. 9, 1–16 (2019).
Kuppusamy, K. T. et al. Let-7 family of microRNA is required for maturation and adult-like metabolism in stem cell-derived cardiomyocytes. Proc. Natl Acad. Sci. USA 112, E2785–E2794 (2015).
Lu, T. Y. et al. Overexpression of microRNA-1 promotes cardiomyocyte commitment from human cardiovascular progenitors via suppressing WNT and FGF signaling pathways. J. Mol. Cell. Cardiol. 63, 146–154 (2013).
Fu, J. D. et al. Distinct roles of microRNA-1 and -499 in ventricular specification and functional maturation of human embryonic stem cell-derived cardiomyocytes. PLoS ONE 6, e27417 (2011).
Poon, E. N. Y. et al. Integrated transcriptomic and regulatory network analyses identify microRNA-200c as a novel repressor of human pluripotent stem cell-derived cardiomyocyte differentiation and maturation. Cardiovasc. Res. 114, 894–906 (2018).
Lee, D. S. et al. Defined microRNAs induce aspects of maturation in mouse and human embryonic-stem-cell-derived cardiomyocytes. Cell Rep. 12, 1960–1967 (2015).
Bassat, E. et al. The extracellular matrix protein agrin promotes heart regeneration in mice. Nature 547, 179–184 (2017).
Zhou, Y. et al. Comparative gene expression analyses reveal distinct molecular signatures between differentially reprogrammed cardiomyocytes. Cell Rep. 20, 3014–3024 (2017).
Moroni, L. et al. Biofabrication strategies for 3D in vitro models and regenerative medicine. Nat. Rev. Mater. 3, 21–37 (2018).
Adv. Mater. 21, 3307–3329 (2009).
Malda, J. et al. 25th anniversary article: engineering hydrogels for biofabrication. Adv. Mater. 25, 5011–5028 (2013).
Lee, S. et al. Contractile force generation by 3D hiPSC-derived cardiac tissues is enhanced by rapid establishment of cellular interconnection in matrix with muscle-mimicking stiffness. Biomaterials 131, 111–120 (2017).
Kerscher, P. et al. Direct hydrogel encapsulation of pluripotent stem cells enables ontomimetic differentiation and growth of engineered human heart tissues. Biomaterials 83, 383–395 (2016).
Nanotechnology 25, 014011 (2014).
Annu. Rev. Biomed. Eng. 16, 247–276 (2014).
Rodriguez, M. L. et al. Measuring the contractile forces of human induced pluripotent stem cell-derived cardiomyocytes with arrays of microposts. J. Biomech. Eng. 136, 051005 (2014).
Biomaterials 27, 3675–3683 (2006).
Biomaterials 32, 3233–3243 (2011).
Ott, H. C. et al. Perfusion-decellularized matrix: using nature’s platform to engineer a bioartificial heart. Nat. Med. 14, 213–221 (2008).
Oberwallner, B. et al. Preparation of cardiac extracellular matrix scaffolds by decellularization of human myocardium. J. Biomed. Mater. Res. A 102, 3263–3272 (2014).
Pati, F. et al. Printing three-dimensional tissue analogues with decellularized extracellular matrix bioink. Nat. Commun. 5, 1–11 (2014).
Perea-Gil, I. et al. A cell-enriched engineered myocardial graft limits infarct size and improves cardiac function: pre-clinical study in the porcine myocardial infarction model. JACC Basic Transl. Sci. 1, 360–372 (2016).
Tissue Eng. Part A 16, 2017–2027 (2010).
Johnson, T. D. et al. Human versus porcine tissue sourcing for an injectable myocardial matrix hydrogel. Biomater. Sci. 2, 735–744 (2014).
Bejleri, D. et al. A bioprinted cardiac patch composed of cardiac-specific extracellular matrix and progenitor cells for heart repair. Adv. Healthc. Mater. 7, 1800672 (2018).
Noor, N. et al. 3D printing of personalized thick and perfusable cardiac patches and hearts. Adv. Sci. 6, 1900344 (2019).
Zhao, Y. et al. A platform for generation of chamber-specific cardiac tissues and disease modeling. Cell 176, 913–927 (2019).
Engelmayr, G. C. et al. Accordion-like honeycombs for tissue engineering of cardiac anisotropy. Nat. Mater. 7, 1003–1010 (2008).
Tian, B. et al. Macroporous nanowire nanoelectronic scaffolds for synthetic tissues. Nat. Mater. 11, 986–994 (2012).
Feiner, R. et al. Engineered hybrid cardiac patches with multifunctional electronics for online monitoring and regulation of tissue function. Nat. Mater. 15, 679–685 (2016).
Proc. Natl Acad. Sci. USA 109, E3414–E3423 (2012).
Zhang, B. et al. Biodegradable scaffold with built-in vasculature for organ-on-a-chip engineering and direct surgical anastomosis. Nat. Mater. 15, 669–678 (2016).
Gouveia, P. J. et al. Flexible nanofilms coated with aligned piezoelectric microfibers preserve the contractility of cardiomyocytes. Biomaterials 139, 213–228 (2017).
Nano Lett. 10, 2257–2261 (2010).
Castilho, M. et al. Melt electrowriting allows tailored microstructural and mechanical design of scaffolds to advance functional human myocardial tissue formation. Adv. Funct. Mater. 28, 1803151 (2018).
Nat. Biotechnol. 32, 773–785 (2014).
Hinton, T. J. et al. Three-dimensional printing of complex biological structures by freeform reversible embedding of suspended hydrogels. Sci. Adv. 1, e1500758 (2015).
Lee, A. et al. 3D bioprinting of collagen to rebuild components of the human heart. Science 365, 482–487 (2019).
Zhang, Y. S. et al. Bioprinting 3D microfibrous scaffolds for engineering endothelialized myocardium and heart-on-a-chip. Biomaterials 110, 45–59 (2016).
Proc. Natl Acad. Sci. USA 113, 3179–3184 (2016).
Grigoryan, B. et al. Multivascular networks and functional intravascular topologies within biocompatible hydrogels. Science 364, 458–464 (2019).
Skylar-Scott, M. A. et al. Biomanufacturing of organ-specific tissues with high cellular density and embedded vascular channels. Sci. Adv. 5, eaaw2459 (2019).
Bernal, P. N. et al. Volumetric bioprinting of complex living-tissue constructs within seconds. Adv. Mater. 31, 1904209 (2019).
Fordyce, C. B. et al. Cardiovascular drug development: is it dead or just hibernating? J. Am. Coll. Cardiol. 65, 1567–1582 (2015).
Trends Pharmacol. Sci. 30, 536–545 (2009).
Annu. Rev. Pharmacol. Toxicol. 58, 83–103 (2018).
Polonchuk, L. et al. Cardiac spheroids as promising in vitro models to study the human heart microenvironment. Sci. Rep. 7, 1–12 (2017).
Lab Chip 13, 3599–3608 (2013).
Marsano, A. et al. Beating heart on a chip: a novel microfluidic platform to generate functional 3D cardiac microtissues. Lab Chip 16, 599–610 (2016).
Feric, N. T. et al. Engineered cardiac tissues generated in the biowire II: a platform for human-based drug discovery. Toxicol. Sci. 172, 89–97 (2019).
Chramiec, A. et al. Integrated human organ-on-a-chip model for predictive studies of anti-tumor drug efficacy and cardiac safety. Lab Chip 20, 4357–4372 (2020).
Lind, J. U. et al. Cardiac microphysiological devices with flexible thin-film sensors for higher-throughput drug screening. Lab Chip 17, 3692–3703 (2017).
Zhao, Y. et al. A multimaterial microphysiological platform enabled by rapid casting of elastic microwires. Adv. Healthc. Mater. 8, 1801187 (2019).
Lab Chip 17, 2395–2420 (2017).
Sun, N. et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci. Transl. Med. 4, 130ra47 (2012).
Burridge, P. W. et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat. Med. 22, 547–556 (2016).
Lan, F. et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 12, 101–113 (2013).
Lee, J. et al. Activation of PDGF pathway links LMNA mutation to dilated cardiomyopathy. Nature 572, 335–340 (2019).
Te Riele, A. S. J. M. et al. Multilevel analyses of SCN5A mutations in arrhythmogenic right ventricular dysplasia/cardiomyopathy suggest non-canonical mechanisms for disease pathogenesis. Cardiovasc. Res. 113, 102–111 (2017).
Kodo, K. et al. iPSC-derived cardiomyocytes reveal abnormal TGF-β signalling in left ventricular non-compaction cardiomyopathy. Nat. Cell Biol. 18, 1031–1042 (2016).
Itzhaki, I. et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 471, 225–230 (2011).
Yazawa, M. et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 471, 230–236 (2011).
Matsa, E. et al. Transcriptome profiling of patient-specific human iPSC-cardiomyocytes predicts individual drug safety and efficacy responses in vitro. Cell Stem Cell 19, 311–325 (2016).
Sharma, A. et al. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sci. Transl. Med. 9, eaaf2584 (2017).
Smith, J. G. W. et al. Isogenic pairs of hiPSC-CMs with hypertrophic cardiomyopathy/LVNC-associated ACTC1 E99K mutation unveil differential functional deficits. Stem Cell Rep. 11, 1226–1243 (2018).
de la Roche, J. et al. Comparing human iPSC-cardiomyocytes versus HEK293T cells unveils disease-causing effects of Brugada mutation A735V of NaV1.5 sodium channels. Sci. Rep. 9, 1–14 (2019).
2+ signaling. Cell Calcium 73, 104–111 (2018).
Mosqueira, D. et al. CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy. Eur. Heart J. 39, 3879–3892 (2018).
Hinson, J. T. et al. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science 349, 982–986 (2015).
Wang, G. et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat. Med. 20, 616–623 (2014).
Goldfracht, I. et al. Generating ring-shaped engineered heart tissues from ventricular and atrial human pluripotent stem cell-derived cardiomyocytes. Nat. Commun. 11, 1–15 (2020).
Proc. Natl Acad. Sci. USA 110, 9770–9775 (2013).
Sadeghi, A. H. et al. Engineered 3D cardiac fibrotic tissue to study fibrotic remodeling. Adv. Healthc. Mater. 6, 1601434 (2017).
Zhang, Y. S. et al. Bioprinted thrombosis-on-a-chip. Lab Chip 16, 4097–4105 (2016).
Vikhorev, P. G. et al. Abnormal contractility in human heart myofibrils from patients with dilated cardiomyopathy due to mutations in TTN and contractile protein genes. Sci. Rep. 7, 1–11 (2017).
Prondzynski, M. et al. Disease modeling of a mutation in α‐actinin 2 guides clinical therapy in hypertrophic cardiomyopathy. EMBO Mol. Med. 11, e11115 (2019).
Madonna, R. et al. Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. Eur. Heart J. 37, 1789–1798 (2016).
Sluijter, J. P. G. et al. Extracellular vesicles in diagnostics and therapy of the ischaemic heart: Position Paper from the Working Group on Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc. Res. 114, 19–34 (2018).
Eschenhagen, T. et al. Cardiomyocyte regeneration: a consensus statement. Circulation 136, 680–686 (2017).
Terrovitis, J. et al. Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. J. Am. Coll. Cardiol. 54, 1619–1626 (2009).
Gaetani, R. et al. Cardiospheres and tissue engineering for myocardial regeneration: potential for clinical application. J. Cell. Mol. Med. 14, 1071–1077 (2010).
Hou, D. et al. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation 112, I-150–I-156 (2005).
Riegler, J. et al. Human engineered heart muscles engraft and survive long term in a rodent myocardial infarction model. Circ. Res. 117, 720–730 (2015).
Pecha, S. et al. Human iPS cell-derived engineered heart tissue does not affect ventricular arrhythmias in a guinea pig cryo-injury model. Sci. Rep. 9, 1–12 (2019).
Weinberger, F. et al. Cardiac repair in guinea pigs with human engineered heart tissue from induced pluripotent stem cells. Sci. Transl. Med. 8, 363ra148 (2016).
Gao, L. et al. Large cardiac muscle patches engineered from human induced-pluripotent stem cell-derived cardiac cells improve recovery from myocardial infarction in swine. Circulation 137, 1712–1730 (2018).
Mawad, D. et al. A conducting polymer with enhanced electronic stability applied in cardiac models. Sci. Adv. 2, e1601007 (2016).
Ye, L. et al. Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells. Cell Stem Cell 15, 750–761 (2014).
Gaetani, R. et al. Epicardial application of cardiac progenitor cells in a 3D-printed gelatin/hyaluronic acid patch preserves cardiac function after myocardial infarction. Biomaterials 61, 339–348 (2015).
Feyen, D. A. M. et al. Gelatin microspheres as vehicle for cardiac progenitor cells delivery to the myocardium. Adv. Healthc. Mater. 5, 1071–1079 (2016).
Li, J. et al. Human pluripotent stem cell-derived cardiac tissue-like constructs for repairing the infarcted myocardium. Stem Cell Rep. 9, 1546–1559 (2017).
Kawamura, M. et al. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation 126, S29–S37 (2012).
Landa, N. et al. Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation 117, 1388–1396 (2008).
Seif-Naraghi, S. B. et al. Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction. Sci. Transl. Med. 5, 173ra25 (2013).
Lin, X. et al. A viscoelastic adhesive epicardial patch for treating myocardial infarction. Nat. Biomed. Eng. 3, 632–643 (2019).
Card. Electrophysiol. Clin. 7, 357–370 (2015).
JAMA Cardiol. 1, 953–962 (2016).
Madonna, R. Human-induced pluripotent stem cells: in quest of clinical applications. Mol. Biotechnol. 52, 193–203 (2012).
Breitbach, M. et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood 110, 1362–1369 (2007).
Blin, G. et al. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J. Clin. Invest. 120, 1125–1139 (2010).
Circulation 109, 3154–3157 (2004).
Adv. Drug Deliv. Rev. 114, 184–192 (2017).
Menasché, P. et al. Transplantation of human embryonic stem cell–derived cardiovascular progenitors for severe ischemic left ventricular dysfunction. J. Am. Coll. Cardiol. 71, 429–438 (2018).
Mewhort, H. E. M. et al. Epicardial infarct repair with bioinductive extracellular matrix promotes vasculogenesis and myocardial recovery. J. Heart Lung Transplant. 35, 661–670 (2016).
J. Thorac. Cardiovasc. Surg. 147, e41–e43 (2014).
J. Thorac. Cardiovasc. Surg. 147, 1650–1659 (2014).
Traverse, J. H. et al. First-in-man study of a cardiac extracellular matrix hydrogel in early and late myocardial infarction patients. JACC Basic Transl. Sci. 4, 659–669 (2019).
Frey, N. et al. Intracoronary delivery of injectable bioabsorbable scaffold (IK-5001) to treat left ventricular remodeling after ST-elevation myocardial infarction: a first-in-man study. Circ. Cardiovasc. Interv. 7, 806–812 (2014).
Rao, S. V. et al. Bioabsorbable intracoronary matrix for prevention of ventricular remodeling after myocardial infarction. J. Am. Coll. Cardiol. 68, 715–723 (2016).
Rao, S. V. et al. A randomized, double-blind, placebo-controlled trial to evaluate the safety and effectiveness of intracoronary application of a novel bioabsorbable cardiac matrix for the prevention of ventricular remodeling after large ST-segment elevation myocardial infarction: Rationale and design of the PRESERVATION I trial. Am. Heart J. 170, 929–937 (2015).
Anker, S. D. et al. A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial). Eur. Heart J. 36, 2297–2309 (2015).
Mann, D. L. et al. One-year follow-up results from AUGMENT-HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure. Eur. J. Heart Fail. 18, 314–325 (2016).
Lee, R. J. et al. The feasibility and safety of Algisyl-LVRTM as a method of left ventricular augmentation in patients with dilated cardiomyopathy: initial first in man clinical results. Int. J. Cardiol. 199, 18–24 (2015).
Puymirat, E. et al. Can mesenchymal stem cells induce tolerance to cotransplanted human embryonic stem cells? Mol. Ther. 17, 176–182 (2009).